Atypical lobular breast hyperplasia

Summary

Atypical lobular breast hyperplasia (MONDO:0006098) is a disease and 7 clinical trials. Top therapeutic interventions include pasireotide and ruxolitinib. A subtype of integumentary system cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 7

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	atypical lobular breast hyperplasia
Mondo ID	MONDO:0006098
EFO	EFO:1000100
NCIT	C4730
SNOMED CT	450697004
UMLS	C1368920
MedGen	277968
Anatomy (UBERON)	UBERON:0018140
Is cancer (heuristic)	no

Also known as: ALH · atypical breast lobular hyperplasia · atypical lobular breast hyperplasia · atypical lobular hyperplasia · atypical lobular hyperplasia of breast · atypical lobular hyperplasia of the breast

Disease family

Classification path: disease › human disease › disease by body system or component › integumentary system disorder › integumentary system cancer › atypical lobular breast hyperplasia

Related subtypes (6): bartholin gland carcinoma, skin cancer, nipple carcinoma, breast adenocarcinoma, breast diffuse large B-cell lymphoma, dermatofibrosarcoma protuberans

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 7.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	4
PHASE2	2
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07499999	PHASE2	NOT_YET_RECRUITING	Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer
NCT02928978	PHASE2	COMPLETED	Ruxolitinib for Premalignant Breast Disease
NCT01372644	PHASE1	COMPLETED	Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor: A Proof of Principle Trial
NCT00620087	Not specified	COMPLETED	Molecular Breast Imaging in Women With Atypia and LCIS
NCT01874184	Not specified	COMPLETED	Group-Based Lifestyle Intervention in Measuring Biomarker Levels in Participants at High Risk for Breast Cancer
NCT03868475	Not specified	WITHDRAWN	Comparing Vacuum-Assisted Percutaneous Excision to Open Surgical Excision for Borderline or High-Risk Breast Lesions
NCT05868252	Not specified	UNKNOWN	Molecular Analysis of the Sloane Project

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
PASIREOTIDE	4	1
RUXOLITINIB	4	1